Stöver H, Michels II, Werse B, Pfeiffer-Gerschel T. Cannabis Regulation in Europe: Country Report Germany. Transnational Institute. 2019.
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Cannabisagentur. Accessed November 8, 2021: https://www.bfarm.de/DE/Bundesopiumstelle/Cannabis-als-Medizin/Cannabisagentur/_node.html
Cansativa GmbH. Distributing German-Cultivated Medical Cannabis Flowers for the German Market on Behalf of the Cannabis Agency (BfArM). 2021. Accessed November 8, 2021: https://www.cansativa.de/wp-content/uploads/20210623_Distributing-German-Cultivated_Cannabis_CSTV_website.pdf
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Cannabisagentur. April 2021. Accessed November 10, 2021: https://www.cannabisagentur.de/wp-content/uploads/Cannabisagentur_AGB_Apotheken.pdf
Prohibition Partners. German Cannabis Cultivation Licenses Awarded to Aphria, Aurora and Demecan. 2019. Accessed November 8, 2021: https://prohibitionpartners.com/2019/04/05/germany-awards-domestic-cultivation-licences-to-aphria-aurora-and-demecan/
Preuss K-J, von Rothkirch C. The Market for Medical Cannabis in Germany. 1st ed. Hamburg: EPC Healthcare GmbH. 2020.
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2): 199-215.
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Häufig gestellte Fragen (FAQ). Accessed November 8, 2021: https://www.bfarm.de/DE/Bundesopiumstelle/_FAQ/Cannabis/faq-liste.html?cms_fid=566334Question:%20Sind%20Nutzhanf-/CBD-Produkte%20aus%20bet%C3%A4ubungsmittelrechtlicher%20Sicht%20verkehrsf%C3%A4hig?%20/%20para%203